Back
CU6
Clarity Pharmaceuticals Ltd
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 60.91%
Annual Growth
4 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
112
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
📈 Performance
Price History
+252.14%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$4.93
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CU6
112
📊 Total Capital Earnings
$373K
🔃 Average investment frequency
37 weeks
💵 Average investment amount
$2,393
⏰ Last time a customer invested in CU6
1 hours
CU6 investor breakdown
💵 Income of investors
More than 200k
6%
150k - 200k
100k - 150k
17%
50k - 100k
35%
Less than 50k
37%
👶 Age of investors
18 - 25
12%
26 - 34
27%
35 - 90
62%
🙋 Legal gender of investors
Female
51%
Male
49%
Pearlers who invest in CU6 also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
8.00%
📊 Share price
$110.43 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
⛳️ DIVERSIFIED
🧱 MATERIALS
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
16.78%
📊 Share price
$152.13 AUD
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
🌏 GLOBAL
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
21.57%
📊 Share price
$68.19 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
🙌 Performance (5Yr p.a)
143.67%
📊 Share price
$14.48 AUD
🕊️ SOCIALLY AWARE
🧬 BIOTECHNOLOGY
DroneShield Ltd. engages in the development and commercialisation of hardware and software technology for drone detection and security. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-06-22. The company provides artificial intelligence-based platforms for protection against advanced threats, such as drones and autonomous systems. The company offers customers bespoke counter-drone (or counter-UAS) and electronic warfare solutions and off-the-shelf products designed to suit a variety of terrestrial, maritime, or airborne platforms. The Company’s products include DroneGun Tactical, DroneGun MKIII, DroneSentry, DroneSentry-C2, DroneSentry-X, RfPatrol and DroneSim among others. The DroneGun Tactical is an unmanned aerial systems (UAS) countermeasure designed for two-hand operation and long-range defeat. RfPatrol is a passive/non-emitting wearable UAS detection device. The Company’s capabilities include C-UAS, C-UxS Training, and Electronic Warfare.
🙌 Performance (5Yr p.a)
556.00%
📊 Share price
$5.76 AUD
🚀 AEROSPACE & DEFENSE
Want more shares? Try these...
